- Home
- MACI vs VYGR Comparison
MACI vs VYGR Comparison
Compare MACI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MACI
- VYGR
- Stock Information
- Founded
- MACI 2024
- VYGR 2013
- Country
- MACI United States
- VYGR United States
- Employees
- MACI N/A
- VYGR N/A
- Industry
- MACI
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- MACI
- VYGR Health Care
- Exchange
- MACI NYSE
- VYGR Nasdaq
- Market Cap
- MACI 221.6M
- VYGR 191.9M
- IPO Year
- MACI 2024
- VYGR 2015
- Fundamental
- Price
- MACI $10.32
- VYGR $3.17
- Analyst Decision
- MACI
- VYGR Strong Buy
- Analyst Count
- MACI 0
- VYGR 9
- Target Price
- MACI N/A
- VYGR $14.86
- AVG Volume (30 Days)
- MACI 9.3K
- VYGR 282.0K
- Earning Date
- MACI 01-01-0001
- VYGR 05-06-2025
- Dividend Yield
- MACI N/A
- VYGR N/A
- EPS Growth
- MACI N/A
- VYGR N/A
- EPS
- MACI N/A
- VYGR N/A
- Revenue
- MACI N/A
- VYGR $66,958,000.00
- Revenue This Year
- MACI N/A
- VYGR N/A
- Revenue Next Year
- MACI N/A
- VYGR $2.04
- P/E Ratio
- MACI $44.17
- VYGR N/A
- Revenue Growth
- MACI N/A
- VYGR N/A
- 52 Week Low
- MACI $9.95
- VYGR $2.75
- 52 Week High
- MACI $10.35
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- MACI N/A
- VYGR 40.49
- Support Level
- MACI N/A
- VYGR $3.46
- Resistance Level
- MACI N/A
- VYGR $3.69
- Average True Range (ATR)
- MACI 0.00
- VYGR 0.18
- MACD
- MACI 0.00
- VYGR 0.00
- Stochastic Oscillator
- MACI 0.00
- VYGR 0.00
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.